Bioceres price target lowered to $16 from $17 at Oppenheimer

Oppenheimer lowered the firm’s price target on Bioceres to $16 from $17 and keeps an Outperform rating on the shares. The firm remains constructive on Bioceres as it exits an uneven recovery year and enters FY25 with a keen focus on working capital and revenue efficiency. Oppenheimer is lowering its FY25 topline outlook for muted growth amid the challenging ag macro backdrop, while strengthening its margin assumptions as the company transitions its go-to-market model for HB4 for capital efficiency.